08:25 AM EST, 01/15/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Wednesday that it has submitted a New Drug Application to the US Food and Drug Administration for its investigational intravesical drug-releasing system TAR-200 in a certain kind of bladder cancer.

The company said TAR-200 is being tested for patients with Bacillus Calmette-Guerin -unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

The submission is based on data from a phase 2b study, which showed an 83.5% complete response rate, Johnson & Johnson ( JNJ ) said.